Cargando…

Serum Anti-Mullerian Hormone Levels Might Indicate Premenopausal Endometrial Lesions

Background: Endometrial proliferative lesions (EPL) usually refer to endometrial hyperplasia (EH) and endometrial cancer (EC). Among patients with premenopausal EPL who wish to preserve their fertility, only those with EH and early-stage EC have the possibility to undergo fertility preservation ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Yao, Yingsha, Shi, Liujing, Zhu, Xiaoming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10650321/
https://www.ncbi.nlm.nih.gov/pubmed/37958197
http://dx.doi.org/10.3390/diagnostics13213301
_version_ 1785135754434838528
author Yao, Yingsha
Shi, Liujing
Zhu, Xiaoming
author_facet Yao, Yingsha
Shi, Liujing
Zhu, Xiaoming
author_sort Yao, Yingsha
collection PubMed
description Background: Endometrial proliferative lesions (EPL) usually refer to endometrial hyperplasia (EH) and endometrial cancer (EC). Among patients with premenopausal EPL who wish to preserve their fertility, only those with EH and early-stage EC have the possibility to undergo fertility preservation therapy. However, there is currently a lack of specific and reliable screening criteria and models for identifying these patients. Methods: This study utilized a retrospective diagnostic study design. The training set included medical record information that met the criteria between August 2017 and October 2022, while the validation set consisted of medical record information that met the criteria from November 2022 to May 2023. The endometrial pathological test served as the gold standard. The serum anti-Mullerian hormone (AMH) level before endometrial sampling and a regression model were employed to predict EPL. Results: The study included a total of 1209 patients with PCOS (1119 in the control group and 90 in the endometrial proliferative lesion group) and 5366 women without PCOS (5249 in the control group and 117 in the proliferative lesion group). In the case of PCOS patients aged 20–39 years, the most effective screening threshold for AMH was found to be a serum AMH level of ≤5.39 ng/mL. The model used for this group was logit(p) = −2.562 − 0.430 × AMH + 0.127 × BMI + 1.512 × hypertension + 0.956 × diabetes −1.145 × regular menstruation. On the other hand, for non-PCOS women aged 20–39 years, the optimal screening threshold for AMH was determined to be a serum AMH value of ≤2.18 ng/mL. The model used for this group was logit(p) = −3.778 − 0.823 × AMH + 0.176 × BMI + 2.660 × diabetes −1.527 × regular menstruation −1.117 × dysmenorrhea. It is important to note that all of these findings have successfully passed internal verification. Conclusion: For PCOS and non-PCOS women aged 20–39 years, the serum AMH test and related multiple regression models were obtained for the warning of EPL.
format Online
Article
Text
id pubmed-10650321
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106503212023-10-25 Serum Anti-Mullerian Hormone Levels Might Indicate Premenopausal Endometrial Lesions Yao, Yingsha Shi, Liujing Zhu, Xiaoming Diagnostics (Basel) Article Background: Endometrial proliferative lesions (EPL) usually refer to endometrial hyperplasia (EH) and endometrial cancer (EC). Among patients with premenopausal EPL who wish to preserve their fertility, only those with EH and early-stage EC have the possibility to undergo fertility preservation therapy. However, there is currently a lack of specific and reliable screening criteria and models for identifying these patients. Methods: This study utilized a retrospective diagnostic study design. The training set included medical record information that met the criteria between August 2017 and October 2022, while the validation set consisted of medical record information that met the criteria from November 2022 to May 2023. The endometrial pathological test served as the gold standard. The serum anti-Mullerian hormone (AMH) level before endometrial sampling and a regression model were employed to predict EPL. Results: The study included a total of 1209 patients with PCOS (1119 in the control group and 90 in the endometrial proliferative lesion group) and 5366 women without PCOS (5249 in the control group and 117 in the proliferative lesion group). In the case of PCOS patients aged 20–39 years, the most effective screening threshold for AMH was found to be a serum AMH level of ≤5.39 ng/mL. The model used for this group was logit(p) = −2.562 − 0.430 × AMH + 0.127 × BMI + 1.512 × hypertension + 0.956 × diabetes −1.145 × regular menstruation. On the other hand, for non-PCOS women aged 20–39 years, the optimal screening threshold for AMH was determined to be a serum AMH value of ≤2.18 ng/mL. The model used for this group was logit(p) = −3.778 − 0.823 × AMH + 0.176 × BMI + 2.660 × diabetes −1.527 × regular menstruation −1.117 × dysmenorrhea. It is important to note that all of these findings have successfully passed internal verification. Conclusion: For PCOS and non-PCOS women aged 20–39 years, the serum AMH test and related multiple regression models were obtained for the warning of EPL. MDPI 2023-10-25 /pmc/articles/PMC10650321/ /pubmed/37958197 http://dx.doi.org/10.3390/diagnostics13213301 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Yao, Yingsha
Shi, Liujing
Zhu, Xiaoming
Serum Anti-Mullerian Hormone Levels Might Indicate Premenopausal Endometrial Lesions
title Serum Anti-Mullerian Hormone Levels Might Indicate Premenopausal Endometrial Lesions
title_full Serum Anti-Mullerian Hormone Levels Might Indicate Premenopausal Endometrial Lesions
title_fullStr Serum Anti-Mullerian Hormone Levels Might Indicate Premenopausal Endometrial Lesions
title_full_unstemmed Serum Anti-Mullerian Hormone Levels Might Indicate Premenopausal Endometrial Lesions
title_short Serum Anti-Mullerian Hormone Levels Might Indicate Premenopausal Endometrial Lesions
title_sort serum anti-mullerian hormone levels might indicate premenopausal endometrial lesions
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10650321/
https://www.ncbi.nlm.nih.gov/pubmed/37958197
http://dx.doi.org/10.3390/diagnostics13213301
work_keys_str_mv AT yaoyingsha serumantimullerianhormonelevelsmightindicatepremenopausalendometriallesions
AT shiliujing serumantimullerianhormonelevelsmightindicatepremenopausalendometriallesions
AT zhuxiaoming serumantimullerianhormonelevelsmightindicatepremenopausalendometriallesions